-
Protein-Ligand Docking Surrogate Models: A SARS-CoV-2 Benchmark for Deep Learning Accelerated Virtual Screening
Authors:
Austin Clyde,
Thomas Brettin,
Alexander Partin,
Hyunseung Yoo,
Yadu Babuji,
Ben Blaiszik,
Andre Merzky,
Matteo Turilli,
Shantenu Jha,
Arvind Ramanathan,
Rick Stevens
Abstract:
We propose a benchmark to study surrogate model accuracy for protein-ligand docking. We share a dataset consisting of 200 million 3D complex structures and 2D structure scores across a consistent set of 13 million "in-stock" molecules over 15 receptors, or binding sites, across the SARS-CoV-2 proteome. Our work shows surrogate docking models have six orders of magnitude more throughput than standa…
▽ More
We propose a benchmark to study surrogate model accuracy for protein-ligand docking. We share a dataset consisting of 200 million 3D complex structures and 2D structure scores across a consistent set of 13 million "in-stock" molecules over 15 receptors, or binding sites, across the SARS-CoV-2 proteome. Our work shows surrogate docking models have six orders of magnitude more throughput than standard docking protocols on the same supercomputer node types. We demonstrate the power of high-speed surrogate models by running each target against 1 billion molecules in under a day (50k predictions per GPU seconds). We showcase a workflow for docking utilizing surrogate ML models as a pre-filter. Our workflow is ten times faster at screening a library of compounds than the standard technique, with an error rate less than 0.01\% of detecting the underlying best scoring 0.1\% of compounds. Our analysis of the speedup explains that to screen more molecules under a docking paradigm, another order of magnitude speedup must come from model accuracy rather than computing speed (which, if increased, will not anymore alter our throughput to screen molecules). We believe this is strong evidence for the community to begin focusing on improving the accuracy of surrogate models to improve the ability to screen massive compound libraries 100x or even 1000x faster than current techniques.
△ Less
Submitted 30 June, 2021; v1 submitted 13 June, 2021;
originally announced June 2021.
-
IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads
Authors:
Aymen Al Saadi,
Dario Alfe,
Yadu Babuji,
Agastya Bhati,
Ben Blaiszik,
Thomas Brettin,
Kyle Chard,
Ryan Chard,
Peter Coveney,
Anda Trifan,
Alex Brace,
Austin Clyde,
Ian Foster,
Tom Gibbs,
Shantenu Jha,
Kristopher Keipert,
Thorsten Kurth,
Dieter Kranzlmüller,
Hyungro Lee,
Zhuozhao Li,
Heng Ma,
Andre Merzky,
Gerald Mathias,
Alexander Partin,
Junqi Yin
, et al. (11 additional authors not shown)
Abstract:
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating…
▽ More
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating the entire process. No single methodological approach can achieve the necessary accuracy with required efficiency. Here we describe multiple algorithmic innovations to overcome this fundamental limitation, development and deployment of computational infrastructure at scale integrates multiple artificial intelligence and simulation-based approaches. Three measures of performance are:(i) throughput, the number of ligands per unit time; (ii) scientific performance, the number of effective ligands sampled per unit time and (iii) peak performance, in flop/s. The capabilities outlined here have been used in production for several months as the workhorse of the computational infrastructure to support the capabilities of the US-DOE National Virtual Biotechnology Laboratory in combination with resources from the EU Centre of Excellence in Computational Biomedicine.
△ Less
Submitted 13 October, 2020;
originally announced October 2020.
-
Targeting SARS-CoV-2 with AI- and HPC-enabled Lead Generation: A First Data Release
Authors:
Yadu Babuji,
Ben Blaiszik,
Tom Brettin,
Kyle Chard,
Ryan Chard,
Austin Clyde,
Ian Foster,
Zhi Hong,
Shantenu Jha,
Zhuozhao Li,
Xuefeng Liu,
Arvind Ramanathan,
Yi Ren,
Nicholaus Saint,
Marcus Schwarting,
Rick Stevens,
Hubertus van Dam,
Rick Wagner
Abstract:
Researchers across the globe are seeking to rapidly repurpose existing drugs or discover new drugs to counter the the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One promising approach is to train machine learning (ML) and artificial intelligence (AI) tools to screen large numbers of small molecules. As a contribution to that effort,…
▽ More
Researchers across the globe are seeking to rapidly repurpose existing drugs or discover new drugs to counter the the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One promising approach is to train machine learning (ML) and artificial intelligence (AI) tools to screen large numbers of small molecules. As a contribution to that effort, we are aggregating numerous small molecules from a variety of sources, using high-performance computing (HPC) to computer diverse properties of those molecules, using the computed properties to train ML/AI models, and then using the resulting models for screening. In this first data release, we make available 23 datasets collected from community sources representing over 4.2 B molecules enriched with pre-computed: 1) molecular fingerprints to aid similarity searches, 2) 2D images of molecules to enable exploration and application of image-based deep learning methods, and 3) 2D and 3D molecular descriptors to speed development of machine learning models. This data release encompasses structural information on the 4.2 B molecules and 60 TB of pre-computed data. Future releases will expand the data to include more detailed molecular simulations, computed models, and other products.
△ Less
Submitted 27 May, 2020;
originally announced June 2020.
